Examkin

Question

Difficulty: HardResearch Ethics and Conflicts of Interest

A 78-year-old man with moderate Alzheimer disease is enrolled in a Phase III randomized, placebo-controlled trial for a novel disease-modifying monoclonal antibody. Prior to enrollment, an independent clinical assessment determined that the patient lacked decision-making capacity for trial participation. His daughter, who is his legally appointed healthcare proxy, provided written informed consent for his enrollment. During the third scheduled infusion, the patient becomes visibly agitated, pulls his arm away, and repeatedly states, "I don't want this, leave me alone." His daughter is present and insists that the clinical nurse administer the infusion, stating, "He doesn't understand what's good for him. This trial is his only hope to slow down the memory loss. Please just give him the medicine." Which of the following is the most appropriate next step in the management of this patient?

  1. Suspend the infusion and respect the patient's dissent to participate in the research.Answer
  2. B
    Proceed with the infusion because the legally authorized proxy has explicitly mandated the treatment.
  3. C
    Halt the infusion and formally reprimand the clinical research coordinator for failing to adequately assess the patient's baseline behavior.
  4. D
    Discuss the patient's refusal with his other adult children in the waiting room to establish a broader family consensus.
  5. E
    Administer a short-acting sedative to ensure compliance, as the trial represents his only potential therapeutic option.

Answer

Suspend the infusion and respect the patient's dissent to participate in the research.
The correct action is to suspend the infusion and respect the patient's dissent. In clinical research involving vulnerable populations, such as individuals with advanced cognitive impairment, the ethical guidelines (e.g., the Belmont Report, Declaration of Helsinki) stipulate strict protections. While a legally authorized representative can provide surrogate consent to enroll the patient, the explicit dissent or refusal of the subject must be honored. Unlike emergency, life-saving clinical care where a proxy's decision might override a patient's lack of capacity to refuse, clinical trials are experimental. Therefore, the patient's physical and verbal refusal constitutes dissent, and the trial procedures must be stopped immediately.

Step-by-Step Solution

1
Identify the patient's capacity and consent status.
The patient lacks capacity, and his legally authorized representative (daughter) provided initial informed consent for the trial.
Establishing the legal foundation for the patient's presence in the study.
2
Evaluate the patient's current behavior against research ethics guidelines (Belmont Report, Common Rule).
The patient is actively displaying physical and verbal dissent ("I don't want this").
Determining if the subject is manifesting dissent or withdrawal of assent.
3
Determine the hierarchy of consent versus dissent in experimental research.
In non-therapeutic or experimental research, the affirmative dissent of a vulnerable subject overrides surrogate consent.
Protecting vulnerable populations from forced participation in research.

Key Concept

Informed Consent and Assent in Vulnerable Populations
Rate this question

Topics

Research Ethics and Conflicts of Interest

More questions from this topic